<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26274504</article-id><article-id pub-id-type="pmc">4537211</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0136019</article-id><article-id pub-id-type="publisher-id">PONE-D-15-12587</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Correlations between Clinical Features and Mortality in Patients with <italic>Vibrio vulnificus</italic> Infection</article-title><alt-title alt-title-type="running-head">VVI Clinical Features Correlated with Its Mortality</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Hong</given-names></name><xref ref-type="aff" rid="aff001"/></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Lichen</given-names></name><xref ref-type="aff" rid="aff001"/></contrib><contrib contrib-type="author"><name><surname>Dong</surname><given-names>Huihui</given-names></name><xref ref-type="aff" rid="aff001"/></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Jianhua</given-names></name><xref ref-type="aff" rid="aff001"/></contrib><contrib contrib-type="author"><name><surname>Gao</surname><given-names>Hainv</given-names></name><xref ref-type="aff" rid="aff001"/></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Meifang</given-names></name><xref ref-type="aff" rid="aff001"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Xuan</given-names></name><xref ref-type="aff" rid="aff001"/></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Xiaoming</given-names></name><xref ref-type="aff" rid="aff001"/></contrib><contrib contrib-type="author"><name><surname>Fan</surname><given-names>Jun</given-names></name><xref ref-type="aff" rid="aff001"/></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Weihang</given-names></name><xref rid="cor001" ref-type="corresp">*</xref><xref ref-type="aff" rid="aff001"/></contrib></contrib-group><aff id="aff001"><addr-line>State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Zhou</surname><given-names>Dongsheng</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Beijing Institute of Microbiology and Epidemiology, CHINA</addr-line></aff><author-notes><fn fn-type="conflict" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con" id="contrib001"><p>Conceived and designed the experiments: WM JF HZ. Performed the experiments: HZ LX HD JH XZ. Analyzed the data: HG MY XC. Contributed reagents/materials/analysis tools: HZ HG MY XC. Wrote the paper: HZ.</p></fn><corresp id="cor001">* E-mail: <email>1510005@zju.edu.cn</email></corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>10</volume><issue>8</issue><elocation-id>e0136019</elocation-id><history><date date-type="received"><day>24</day><month>3</month><year>2015</year></date><date date-type="accepted"><day>30</day><month>7</month><year>2015</year></date></history><permissions><copyright-year>2015</copyright-year><copyright-holder>Zhao et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0136019.pdf"/><abstract><p><italic>Vibrio vulnificus</italic> is a common gram-negative bacterium, which might cause morbidity and mortality in patients following consumption of seafood or exposure to seawater in Southeast China. We retrospectively analyzed clinical data of patients with laboratory confirmed <italic>V</italic>. <italic>vulnificus</italic> infection. Twenty one patients were divided into a survival group and a non-surviving (or death) group according to their clinical outcome. Clinical data and measurements were statistically analyzed. Four patients (19.05%) died and five patients gave positive cultures from bile fluid, and 16 other patients gave positive culture from blood or blisters. Ten patients (47.62%) had an underlying liver disease and marine-related events were found in sixteen patients (76.2%). Patients with heavy drinking habits might be at increased mortality (p = 0.028). Clinical manifestations of cellulitis (47.6%), septic shock (42.9%) and multiple organ failure (28.6%) were statistically significant when comparing survivors and non-survivors (p = 0.035, p = 0.021 and p = 0.003, respectively). The laboratory results, including hemoglobin &#x0003c; 9.0 g/L (p = 0.012), platelets &#x0003c; 2.0&#x000d7;10<sup>9</sup> /L, prothrombin time activity (PTA) &#x0003c;20%, decreased serum creatinine and increased urea nitrogen were statistically significant (p = 0.012, p = 0.003, p = 0.028 and p = 0.028, respectively). Patients may be at a higher risk of mortality under situations where they have a history of habitual heavy alcoholic drink consumption (p = 0.028, OR = 22.5, 95%CI 1.5&#x02013;335.3), accompanied with cellulitis, shock, multiple organ failure, and laboratory examinations that are complicated by decreased platelets, hemoglobin and significantly prolonged prothrombin time (PT).</p></abstract><funding-group><funding-statement>The authors have no support or funding to report.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="3"/><page-count count="9"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p><italic>Vibrio vulnificus</italic> is a gram-negative, curved, rod-shaped bacterium that is present in warm seawater and is a member of a group of vibrios that are called halophilic bacteria. Roland <italic>et al</italic>. reported the first clinical case of <italic>V</italic>. <italic>vulnificus</italic> infection (VVI) that presented with leg gangrene after exposure to sea water in 1970 [<xref rid="pone.0136019.ref001" ref-type="bibr">1</xref>]. Additionally, Hollis <italic>et al</italic>. first isolated this bacteria from blood and defined the laboratory characteristics of this pathogen in 1976 [<xref rid="pone.0136019.ref002" ref-type="bibr">2</xref>]. Moreover, the first clinical characteristics and epidemiological description of 39 patients with VVI were reported in 1979 by Blake <italic>et al</italic> [<xref rid="pone.0136019.ref003" ref-type="bibr">3</xref>]. Not until 1979, Farmer and his group named this pathogen as <italic>V</italic>. <italic>vulnificus</italic> [<xref rid="pone.0136019.ref004" ref-type="bibr">4</xref>].</p><p>Some individuals might be more easily infected with <italic>V</italic>. <italic>vulnificus</italic> following consumption of contaminated seafood or following exposure of an open wound to seawater, especially in situations where there is underlying chronic liver disease [<xref rid="pone.0136019.ref005" ref-type="bibr">5</xref>]. Healthy individuals infected with <italic>V</italic>. <italic>vulnificus</italic> though ingestion present with fever, chills, vomiting, diarrhea, and abdominal pain. Some immuno-compromised subjects that are infected with this bacterium might present with a severe and life-threatening illness that is characterized by septic shock and blistering skin lesions [<xref rid="pone.0136019.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0136019.ref006" ref-type="bibr">6</xref>].</p><p>The hospitalization rate for VVI was more than 80% and the mortality rate was more than 30% in the USA [<xref rid="pone.0136019.ref007" ref-type="bibr">7</xref>]. In China, the mortality rate ranged from approximately 18% to 56% [<xref rid="pone.0136019.ref008" ref-type="bibr">8</xref>&#x02013;<xref rid="pone.0136019.ref013" ref-type="bibr">13</xref>]. Patients with some additional susceptibility factors might have a much higher risk of death such as the presence of chronic disease, heavy drinking habits, diabetes, malignancy, renal disease, delay of treatment, and health-compromising factors [<xref rid="pone.0136019.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0136019.ref009" ref-type="bibr">9</xref>].</p><p>In the current study, we retrospectively analyzed the clinical data of patients with laboratory-confirmed VVI in our hospital and we tried to identify the independent predictors of mortality with the over-arching objective of improving the survival of these patients.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and Methods</title><sec id="sec003"><title>Patients</title><p>From January 2000 to October 2014, patients that presented with laboratory-confirmed VVI were enrolled in our hospital. The medical records were reviewed, and included analysis of the following: demographics, clinical characteristics, laboratory results, treatment history, the time between the onset of the condition, and arrival at our hospital, and hospitalization. All of the patients with laboratory-confirmed infections were divided into a survival group and a non-survival or death group according to their clinical outcomes (Details were shown in <xref rid="pone.0136019.s001" ref-type="supplementary-material">S1 Table</xref>).</p></sec><sec id="sec004"><title>Ethics Statement</title><p>All the patients signed written informed consent, and the Ethics Committee of our hospital, the Medical ethics committee of the First Affiliated Hospital, College of Medicine, Zhejiang University, approved the study, which conformed to the ethical guidelines of the Helsinki Declaration.</p></sec><sec id="sec005"><title>Diagnostic criteria</title><p>Mortality was defined as death during hospitalization or via telephone follow-up confirming death after being discharged from our hospital. Excessive drinking habits, was defined as more than one alcoholic beverage per day for women, and more than two alcoholic beverages per day for men[<xref rid="pone.0136019.ref014" ref-type="bibr">14</xref>]. Septic shock was diagnosed according to the guidelines that were established in 2001[<xref rid="pone.0136019.ref015" ref-type="bibr">15</xref>]. Phlegmon was defined as inflammation of the connective tissue, especially the subcutaneous connective tissue, which was usually suppurative.</p></sec><sec id="sec006"><title>Statistical Analysis</title><p>Statistical Package for the Social Sciences version 16.0 for Windows (SPSS Inc., Chicago, IL, USA) was used for data analyses. Descriptive statistics are shown as mean &#x000b1; standard deviation for continuous data and percentages for categorical data [<xref rid="pone.0136019.ref009" ref-type="bibr">9</xref>]. Between-group differences in continuous data were tested using the Mann&#x02013;Whitney U test. Categorical variables were analyzed using either the Pearson &#x003c7;<sup>2</sup> test or Fisher&#x02019;s exact test [<xref rid="pone.0136019.ref009" ref-type="bibr">9</xref>]. All tests for significance were two-sided, and <italic>p</italic> values &#x0003c; 0.05 were considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec007"><title>Results</title><sec id="sec008"><title>Epidemiology of VVIs</title><p>Twenty one patients were diagnosed with laboratory-confirmed VVIs at our hospital during the past 14 years. The majority of these patients (20/21, 95.2%) were infected between May and October (<xref rid="pone.0136019.g001" ref-type="fig">Fig 1</xref>), and all patients came from Southeast China.</p><fig id="pone.0136019.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0136019.g001</object-id><label>Fig 1</label><caption><title>Seasonal distribution of <italic>V</italic>. <italic>vulnificus</italic> infections at the First Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China.</title></caption><graphic xlink:href="pone.0136019.g001"/></fig></sec><sec id="sec009"><title>Demographics and clinical manifestations caused by <italic>V</italic>. <italic>vulnificus</italic></title><p>Sixteen of the 21 patients presented with evidence of soft tissue infections, of which eight were diagnosed with sepsis, and three had abdomen infections. Meanwhile, eight patients were confirmed by blister fluid culture, six patients were confirmed by blood culture, and five patients were confirmed by bile fluid culture. Fourteen of the patients were males and seven were women among the 21 recruited patients. The mean age was 54.57 &#x000b1; 8.58 years (ranging from 39 to 68 years). Four patients died, and the mortality rate was 19.05%. Marine-related events were found in 16 patients (16/21, 76.2%) including 13 patients that were injured while handling marine animals or exposed to seawater, and three patients who had consumed seafood. Five patients had an unknown history of events. Also, two patients that did not present with any clinical manifestations that were caused by VVI were positive for <italic>V</italic>. <italic>vulnificus</italic> by bile fluid culture following cholecystectomy due to gallbladder stones. The most common clinical symptoms were fever (100%, 21/21) and pain (76.2%, 16/21). Hemorrhagic bullas were seen in 52.4% (11/21) and swellings were present in 61.9% (13/21) of patients. Higher mortality rates were seen in patients with cellulitis (47.6%, 10/21, p = 0.035, OR = 1.7, 95% CI 1.0&#x02013;2.8), septic shock (42.9%, 9/21, p = 0.021, OR = 1.8, 95% CI 1.0&#x02013;3.2) and multiple organ failure (28.6%, 6/21, p = 0.003, OR = 3.0, 95% CI 1.0&#x02013;9.3) (<xref rid="pone.0136019.t001" ref-type="table">Table 1</xref>, <xref rid="pone.0136019.g002" ref-type="fig">Fig 2</xref>, <xref rid="pone.0136019.g003" ref-type="fig">Fig 3</xref>).</p><fig id="pone.0136019.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0136019.g002</object-id><label>Fig 2</label><caption><title>Clinical syndromes of <italic>V</italic>. <italic>vulnificus</italic> infections in the First Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China.</title></caption><graphic xlink:href="pone.0136019.g002"/></fig><fig id="pone.0136019.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0136019.g003</object-id><label>Fig 3</label><caption><title><italic>V</italic>. <italic>vulnificus</italic> infection that presented as swelling, Hemorrhagic bulla and phlegmon are observed on the right hand.</title></caption><graphic xlink:href="pone.0136019.g003"/></fig><table-wrap id="pone.0136019.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0136019.t001</object-id><label>Table 1</label><caption><title>Demographic and clinical presentations.</title></caption><alternatives><graphic id="pone.0136019.t001g" xlink:href="pone.0136019.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="center" rowspan="1" colspan="1">Survivors (n = 17)</th><th align="left" rowspan="1" colspan="1">Deaths (n = 4)</th><th align="left" rowspan="1" colspan="1">OR(95%CI)</th><th align="left" rowspan="1" colspan="1">p-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Mean &#x000b1; SD</td><td align="left" rowspan="1" colspan="1">54.82 &#x000b1; 8.74</td><td align="left" rowspan="1" colspan="1">53.50 &#x000b1; 9.00</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">0.789</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Range</td><td align="left" rowspan="1" colspan="1">39&#x02013;68</td><td align="left" rowspan="1" colspan="1">42&#x02013;64</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Gender</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Male/female</td><td align="left" rowspan="1" colspan="1">10/7</td><td align="left" rowspan="1" colspan="1">4/0</td><td align="left" rowspan="1" colspan="1">0.7(0.5&#x02013;1.0)</td><td align="char" char="." rowspan="1" colspan="1">0.255</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood type</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;A/B/O/AB</td><td align="left" rowspan="1" colspan="1">4/4/6/3</td><td align="left" rowspan="1" colspan="1">2/2/0/0</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">0.091</td></tr><tr><td align="left" rowspan="1" colspan="1">Comorbidities</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;None</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.9(0.1&#x02013;11.5)</td><td align="char" char="." rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Heavy drinking</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">22.5(1.5&#x02013;335.3)</td><td align="char" char="." rowspan="1" colspan="1">0.028</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Liver disease<xref rid="t001fn002" ref-type="table-fn"><sup>&#x00026;</sup></xref></td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.3(0.0&#x02013;3.5)</td><td align="char" char="." rowspan="1" colspan="1">0.586</td></tr><tr><td align="left" rowspan="1" colspan="1">Clinical symptoms</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Fever</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Pain</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1.3(1.0&#x02013;1.8)</td><td align="char" char="." rowspan="1" colspan="1">0.532</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Swelling</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1.4(1.0&#x02013;2.1)</td><td align="char" char="." rowspan="1" colspan="1">0.131</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Hemorrhagic bulla</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0.9(0.1&#x02013;7.9)</td><td align="char" char="." rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Cellulitis</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1.7(1.0&#x02013;2.8)</td><td align="char" char="." rowspan="1" colspan="1">0.035</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Gastrointestinal discomforts<xref rid="t001fn003" ref-type="table-fn">*</xref></td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.7(0.5&#x02013;1.0)</td><td align="char" char="." rowspan="1" colspan="1">0.255</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Septic shock</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1.8(1.0&#x02013;3.2)</td><td align="char" char="." rowspan="1" colspan="1">0.021</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Multiple organ failure</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">3.0 (1.0&#x02013;9.3)</td><td align="char" char="." rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1">Pathogens cultured site</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Bile/not bile culture</td><td align="left" rowspan="1" colspan="1">5/12</td><td align="left" rowspan="1" colspan="1">3/1</td><td align="left" rowspan="1" colspan="1">1.3(1.0&#x02013;5.8)</td><td align="char" char="." rowspan="1" colspan="1">0.532</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>Note</p></fn><fn id="t001fn002"><p><sup>&#x00026;</sup>: Chronic liver diseases include hepatitis B, and C, alcoholic hepatitis, liver cirrhosis, liver transplantation, and liver hepatic carcinoma.</p></fn><fn id="t001fn003"><p>*: Gastrointestinal discomfort including abdominal pain, vomiting, and diarrhea.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec010"><title>Laboratory results of VVI</title><p>The laboratory results measured at the time the patients presented to our hospital (<xref rid="pone.0136019.t002" ref-type="table">Table 2</xref>) and showed that hemoglobin levels &#x0003c; 9.0g/L (p = 0.012, OR = 12.6, 95%CI 11.8&#x02013;92.7), platelets &#x0003c; 2.0&#x000d7;10<sup>9</sup>/L (p = 0.012, OR = 12.6, 95%CI 11.8&#x02013;92.7), PTA &#x0003c; 20% (p = 0.003, OR = 18.0, 95%CI 2.7&#x02013;121.0), and decreased serum creatinine (p = 0.028, OR = 9.6, 95%CI 1.3&#x02013;73.0) and increased urea nitrogen (p = 0.028, OR = 9.6, 95%CI 1.3&#x02013;73.0) all predicted a significantly higher mortality.</p><table-wrap id="pone.0136019.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0136019.t002</object-id><label>Table 2</label><caption><title>Laboratory results measured between survivors group and deaths group.</title></caption><alternatives><graphic id="pone.0136019.t002g" xlink:href="pone.0136019.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Laboratory results</th><th align="left" rowspan="1" colspan="1">Survivors(n = 17)</th><th align="left" rowspan="1" colspan="1">Deaths (n = 4)</th><th align="left" rowspan="1" colspan="1">p-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">WBC (mean &#x000b1; SD, &#x000d7;10<sup>9</sup>/L)</td><td align="left" rowspan="1" colspan="1">6.87 &#x000b1; 4.59</td><td align="left" rowspan="1" colspan="1">11.53 &#x000b1; 9.65</td><td align="char" char="." rowspan="1" colspan="1">0.158</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e; 10&#x000d7;10<sup>9</sup>/L</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003c; 4&#x000d7;10<sup>9</sup>/L</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemoglobin (mean &#x000b1; SD, g/L)</td><td align="left" rowspan="1" colspan="1">111.94 &#x000b1; 16.57</td><td align="left" rowspan="1" colspan="1">87.00 &#x000b1; 8.98</td><td align="char" char="." rowspan="1" colspan="1">0.010</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003c; 90 g/L</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" rowspan="1" colspan="1">Platelets</td><td align="left" rowspan="1" colspan="1">85.24 &#x000b1; 61.65</td><td align="left" rowspan="1" colspan="1">8.75 &#x000b1; 1.50</td><td align="char" char="." rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003c; 2.0&#x000d7;10<sup>9</sup>/L</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" rowspan="1" colspan="1">PT (mean &#x000b1; SD, s)</td><td align="left" rowspan="1" colspan="1">17.38 &#x000b1; 4.85</td><td align="left" rowspan="1" colspan="1">42.30 &#x000b1; 5.31</td><td align="char" char="." rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;PTA&#x0003c;20%</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1">Total bilirubin (mean &#x000b1; SD, mmol/L)</td><td align="left" rowspan="1" colspan="1">95.58 &#x000b1; 84.51</td><td align="left" rowspan="1" colspan="1">198.67 &#x000b1; 169.67</td><td align="char" char="." rowspan="1" colspan="1">0.165</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x0003e;increased / normal</td><td align="left" rowspan="1" colspan="1">6/11</td><td align="left" rowspan="1" colspan="1">2/2</td><td align="char" char="." rowspan="1" colspan="1">0.618</td></tr><tr><td align="left" rowspan="1" colspan="1">ALT (mean &#x000b1; SD, U/L)</td><td align="left" rowspan="1" colspan="1">90.00 &#x000b1; 94.35</td><td align="left" rowspan="1" colspan="1">169 &#x000b1; 175.81</td><td align="char" char="." rowspan="1" colspan="1">0.313</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e;2 times ULN/normal</td><td align="left" rowspan="1" colspan="1">6/11</td><td align="left" rowspan="1" colspan="1">1/3</td><td align="char" char="." rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">AST (mean &#x000b1; SD, U/L)</td><td align="left" rowspan="1" colspan="1">125.30&#x000b1;91.06</td><td align="left" rowspan="1" colspan="1">814.00 &#x000b1; 1045.36</td><td align="char" char="." rowspan="1" colspan="1">0.372</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e;2 times ULN/ normal</td><td align="left" rowspan="1" colspan="1">6/11</td><td align="left" rowspan="1" colspan="1">3/1</td><td align="char" char="." rowspan="1" colspan="1">0.272</td></tr><tr><td align="left" rowspan="1" colspan="1">Serum creatinine (mean &#x000b1; SD, &#x003bc;mol/L)</td><td align="left" rowspan="1" colspan="1">83.30 &#x000b1; 50.95</td><td align="left" rowspan="1" colspan="1">375.00 &#x000b1; 257.46</td><td align="char" char="." rowspan="1" colspan="1">0.187</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003c; normal / normal</td><td align="left" rowspan="1" colspan="1">2/15</td><td align="left" rowspan="1" colspan="1">3/1</td><td align="char" char="." rowspan="1" colspan="1">0.028</td></tr><tr><td align="left" rowspan="1" colspan="1">Urea nitrogen (mean &#x000b1; SD, mmol/L)</td><td align="left" rowspan="1" colspan="1">7.044 &#x000b1; 4.07</td><td align="left" rowspan="1" colspan="1">34.96 &#x000b1; 16.97</td><td align="char" char="." rowspan="1" colspan="1">0.182</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02265;normal / normal</td><td align="left" rowspan="1" colspan="1">2/15</td><td align="left" rowspan="1" colspan="1">3/1</td><td align="char" char="." rowspan="1" colspan="1">0.028</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>Note: ULN, the upper limit of normal. At our hospital, the normal range for ALT was 5&#x02013;40 U/L, the normal range for AST was 5&#x02013;37 U/L, the normal range for serum creatinine was 40&#x02013;108 &#x003bc;mol/L, and the normal range for urea nitrogen was 1.7&#x02013;8.3 mmol/L.</p></fn></table-wrap-foot></table-wrap><p>These clinical isolates were tested for susceptibility to meropenem or imipenem, piperacillin, piperacillin/tazobactam, cefepime, cefoperazone/sulbactam, cefotaxime, ceftazidime, ciprofloxacin, cotrimoxazole, levofloxacin. One bacterial isolate was resistant to imipenem, piperacillin/tazobactam, cefoperazone/sulbactam, cefotaxime, ceftazidime, ciprofloxacin, cotrimoxazole, and levofloxacin. However, it was sensitive to tigecycline.</p></sec><sec id="sec011"><title>Treatment strategies and clinical outcomes in patients with <italic>V</italic>. <italic>vulnificus</italic></title><p>The time of treatment, hospitalization, antibiotics strategies, the course of treatment, and mortality seen between the survival group and the non-survival group are summarized in <xref rid="pone.0136019.t003" ref-type="table">Table 3</xref>.</p><table-wrap id="pone.0136019.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0136019.t003</object-id><label>Table 3</label><caption><title>Treatment strategies and clinical outcomes.</title></caption><alternatives><graphic id="pone.0136019.t003g" xlink:href="pone.0136019.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Treatment strategies</th><th align="left" rowspan="1" colspan="1">Survivors(n = 17)</th><th align="left" rowspan="1" colspan="1">Deaths (n = 4)</th><th align="left" rowspan="1" colspan="1">p-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Antibiotic treatments</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">0.272</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Only on antibiotic</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Piperacillin-tazobactam</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Cefoperazone-sulbactam</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Imipenem-cilastatin</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Meropenem</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Quinolone</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">More than one antibiotic</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Surgical interventions</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Yes/No</td><td align="left" rowspan="1" colspan="1">5/12</td><td align="left" rowspan="1" colspan="1">0/4</td><td align="char" char="." rowspan="1" colspan="1">0.532</td></tr><tr><td align="left" rowspan="1" colspan="1">The time between the injuries or the onset of symptoms to hospital (mean &#x000b1; SD, day)</td><td align="left" rowspan="1" colspan="1">2.29&#x000b1;2.34</td><td align="left" rowspan="1" colspan="1">2.25&#x000b1;0.96</td><td align="char" char="." rowspan="1" colspan="1">0.971</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003c;one /&#x0003e;one</td><td align="left" rowspan="1" colspan="1">10/7</td><td align="left" rowspan="1" colspan="1">3/1</td><td align="char" char="." rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Range</td><td align="left" rowspan="1" colspan="1">1&#x02013;10</td><td align="left" rowspan="1" colspan="1">1&#x02013;3</td><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Hospitalization (mean &#x000b1; SD, day)</td><td align="left" rowspan="1" colspan="1">39.71&#x000b1;32.49</td><td align="left" rowspan="1" colspan="1">15.00&#x000b1;8.72</td><td align="char" char="." rowspan="1" colspan="1">0.155</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Range</td><td align="left" rowspan="1" colspan="1">7&#x02013;109</td><td align="left" rowspan="1" colspan="1">2&#x02013;20</td><td align="char" char="." rowspan="1" colspan="1"/></tr></tbody></table></alternatives></table-wrap><p>The mean time between injuries or the onset of symptoms to hospitalization in the survival group was 2.29 &#x000b1; 2.34 days (ranging from 1 to 3 days) and 2.25 &#x000b1; 0.96 days (ranging from 1 to 10 days) in the non-survival group (t = 0.036, p = 0.971). The mean time of hospitalization was 39.71 &#x000b1; 32.49 days (ranging from 7 to 109 days) in the survival group and 15.00 &#x000b1; 8.72 days (ranging from 2 to 20 days) in the non-survival group (t = 1.481, p = 0.155).</p><p>All patients used antibiotics after admission, and six patients used only one antibiotic and 11 patients used more than one antibiotic in the survival group as compared with the non-survival group where there were three patients that used only one antibiotic, and one patient used more than one antibiotic (p = 1.000). There was no significant difference seen in survival outcome between patients that underwent surgery and those patients that did not undergo surgery (p = 0.532).</p></sec></sec><sec sec-type="conclusions" id="sec012"><title>Discussion</title><p><italic>V</italic>. <italic>vulnificus</italic> is found worldwide in warm coastal waters. Infections with <italic>V</italic>. <italic>vulnificus</italic> are commonly fatal, and the speed and accuracy of diagnosis and treatment is directly linked to mortality [<xref rid="pone.0136019.ref005" ref-type="bibr">5</xref>]. At our hospital, the 19.05% mortality was less than most that were previously reported, and the decreased mortality can be explained due to early diagnosis and appropriate treatment [<xref rid="pone.0136019.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0136019.ref015" ref-type="bibr">15</xref>]. First, all patients came from the Southeast of China and most of these patients (20/21, 95.2%) were infected during the periods of May to October. Meanwhile, 76.2% (16/21) of the patients presented with evidence of soft tissue infections and 76.2% (16/21) of these patients had a positive history of marine-related events. All of these clinical findings allowed us to make an early diagnosis. Second, all of our patients were treated with antibiotics at our hospital. Most patients chose third-generation cephalosporin or the penicillin compound preparation, carbapenemin. In addition, some of the patients chose one of those antibiotics plus tetracycline, and those antibiotics had proven effective against VVIs [<xref rid="pone.0136019.ref005" ref-type="bibr">5</xref>].</p><p>One of the more interesting outcomes from our study is that in our tests, there were two patients who did not have any clinical manifestation caused by VVI, and yet these patients were bile fluid culture positive for <italic>V</italic>. <italic>vulnificus</italic> after cholecystectomy, due in part to gallbladder stones. We may safely conclude that <italic>V</italic>. <italic>vulnificus</italic> may actually become an invisible infection, and the pathogens could lurk undetected <italic>in vivo</italic> (e.g., in the gallbladder as we had demonstrated). It is possible for human subjects to be infected when the body's immunological resistance is dampened or transiently immuno-compromised [<xref rid="pone.0136019.ref005" ref-type="bibr">5</xref>].</p><p>Some high-risk patients may be infected following consumption or from handling contaminated seafood or exposing open wounds to saltwater, such as chronic liver disease, immunodeficiency, end-stage renal disease, alcoholism, and diabetes mellitus, among others [<xref rid="pone.0136019.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0136019.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0136019.ref010" ref-type="bibr">10</xref>,<xref rid="pone.0136019.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0136019.ref016" ref-type="bibr">16</xref>]. In our present study, those who are also suffering from chronic liver disease and diabetes mellitus did not affect the patients&#x02019; survival rate, while habitual heavy drinking affected the overall survival rate of patients with VVI.</p><p>Some studies have identified clinical indicators for the early diagnosis and surgical treatment of VVIs. Hong <italic>et al</italic>. found the time from first presentation of symptoms to hospital admission and limb lesions that involved the trunk might affect the prognosis of the patient [<xref rid="pone.0136019.ref010" ref-type="bibr">10</xref>]. Lee <italic>et al</italic>. found that the number of operations will affect survival [<xref rid="pone.0136019.ref009" ref-type="bibr">9</xref>]. In our series, however, we found that the time between injuries or the first presentation of symptoms when appearing at the hospital, and the appearance of hemorrhagic bulla, did not affect the prognosis of the patient.</p><p>We believe that the number of patients who died or had undergone surgical operations was less than others had reported. Additionally, most patients were treated with antibiotics before arriving at our hospital, and the real time from appearance of symptoms to hospital admission might be less than our statistical time. Similar to other previous studies, the time of hospitalization between the survival and non-survival groups was very similar [<xref rid="pone.0136019.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0136019.ref010" ref-type="bibr">10</xref>]. From our limited set of data, we might infer that the time of hospitalization for the non-survival group was less than the survival group, but this conclusion has to be clearly demonstrated in a larger number of patients.</p><p>Tsai <italic>et al</italic>. statistically analyzed patients that presented with Vibrio necrotizing fasciitis and revealed that a systolic blood pressure of 90 mmHg, low platelet counts, and a combination of hepatic dysfunction were associated with a higher mortality rate [<xref rid="pone.0136019.ref016" ref-type="bibr">16</xref>]. In addition, Chou <italic>et al</italic>. studied 119 adult patients that were hospitalized for VVIs, and their statistical analysis revealed that a high degree of organ dysfunction or a high infection score (or both) were associated with mortality [<xref rid="pone.0136019.ref011" ref-type="bibr">11</xref>].</p><p>In our study, we found in some patients that cellulitis, septic shock and multiple organ failure will all affect mortality (p = 0.035, OR = 1.7, 95%CI 1.0&#x02013;2.8; p = 0.021, OR = 1.8, 95%CI 1.0&#x02013;3.2; and p = 0.003, OR = 3.0, 95%CI 1.0&#x02013;9.3 respectively). Meanwhile, adverse laboratory results also affected mortality in some patients and these included hemoglobin &#x0003c; 9.0g/L (p = 0.012, OR = 12.6, 95%CI 11.8&#x02013;92.7), platelets &#x0003c; 2.0&#x000d7;10<sup>9</sup>/L (p = 0.012, OR = 12.6, 95%CI 11.8&#x02013;92.7), PTA &#x0003c; 20% (p = 0.003, OR = 18.0, 95%CI 2.7&#x02013;121.0), decreased serum creatinine (p = 0.028, OR = 9.6, 95%CI 1.3&#x02013;73.0) and a urea nitrogen that is increased (p = 0.028, OR = 9.6, 95%CI 1.3&#x02013;73.0). Cellulitis affects survival, as has been previously reported by Hong <italic>et al</italic>. [<xref rid="pone.0136019.ref010" ref-type="bibr">10</xref>]. In addition, in laboratory tests, PTA &#x0003c; 20% represented serious hepatic dysfunction. Moreover, under conditions of decreased serum creatinine and increased urea nitrogen, these might be associated with renal dysfunction. All of these laboratory findings revealed multiple organ dysfunction. Meanwhile, low platelet counts (&#x0003c; 2.0&#x000d7;10<sup>9</sup>/L), and decreased hemoglobin (&#x0003c; 9.0 g/L) were consistent with previously reported other studies [<xref rid="pone.0136019.ref011" ref-type="bibr">11</xref>].</p><p>In conclusion, some patients with risk factors consistent with susceptibility to VVI, and who have acute sepsis, fever, cellulitis, and skin hemorrhagic bullae, should be highly suspected of showing VVI, especially in the summer or autumn seasons. Patients may be at a higher risk of mortality under situations where they have a history of habitual heavy alcoholic drink consumption, accompanied with cellulitis, shock, multiple organ failure, and laboratory examinations that are complicated by decreased platelets, hemoglobin and significantly prolonged PT. To prevent VVI, we have to enhance health awareness, and individuals have to avoid consumption of raw seafood, be aware of the risks of damaged skin or open wounds, or mucosal injury, avoid contact with or submersion in sea water. Early diagnosis and selection of appropriate antibiotics are critical factors in attempts aimed at saving the patient's life.</p></sec><sec sec-type="supplementary-material" id="sec013"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0136019.s001"><label>S1 Table</label><caption><title>Descriptive data of subjects in the study.</title><p>(XLS)</p></caption><media xlink:href="pone.0136019.s001.xls"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors thank all of the participants who recruited patients in this study.</p></ack><ref-list><title>References</title><ref id="pone.0136019.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Roland</surname><given-names>FP</given-names></name>. <article-title>Leg gangrene and endotoxin shock due to vibrio parahaemolyticus&#x02014;an infection acquired in New England coastal waters</article-title>. <source>N Engl J Med</source>. <year>1970</year>; <volume>282</volume>: <fpage>1306</fpage>.<pub-id pub-id-type="pmid">5442360</pub-id></mixed-citation></ref><ref id="pone.0136019.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Hollis</surname><given-names>DG</given-names></name>, <name><surname>Weaver</surname><given-names>RE</given-names></name>, <name><surname>Baker</surname><given-names>CN</given-names></name>, <name><surname>Thornsberry</surname><given-names>C</given-names></name>. <article-title>Halophilic Vibrio species isolated from blood cultures</article-title>. <source>J Clin Microbiol</source>. <year>1976</year>; <volume>3</volume>: <fpage>425</fpage>&#x02013;<lpage>431</lpage>. <pub-id pub-id-type="pmid">1262454</pub-id></mixed-citation></ref><ref id="pone.0136019.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Blake</surname><given-names>PA</given-names></name>, <name><surname>Merson</surname><given-names>MH</given-names></name>, <name><surname>Weaver</surname><given-names>RE</given-names></name>, <name><surname>Hollis</surname><given-names>DG</given-names></name>, <name><surname>Heublein</surname><given-names>PC</given-names></name>. <article-title>Disease caused by a marine Vibrio. Clinical characteristics and epidemiology</article-title>. <source>N Engl J Med</source>. <year>1979</year>; <volume>300</volume>: <fpage>1</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="pmid">758155</pub-id></mixed-citation></ref><ref id="pone.0136019.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Farmer</surname><given-names>JJ</given-names><suffix>3rd</suffix></name>. <article-title>Vibrio ("Beneckea") vulnificus, the bacterium associated with sepsis, septicaemia, and the sea</article-title>. <source>Lancet</source>. <year>1979</year>; <volume>2</volume>: <fpage>903</fpage>.<pub-id pub-id-type="pmid">90993</pub-id></mixed-citation></ref><ref id="pone.0136019.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Bross</surname><given-names>MH</given-names></name>, <name><surname>Soch</surname><given-names>K</given-names></name>, <name><surname>Morales</surname><given-names>R</given-names></name>, <name><surname>Mitchell</surname><given-names>RB</given-names></name>. <article-title>Vibrio vulnificus infection: diagnosis and treatment</article-title>. <source>Am Fam Physician</source>. <year>2007</year>; <volume>76</volume>: <fpage>539</fpage>&#x02013;<lpage>544</lpage>. <pub-id pub-id-type="pmid">17853628</pub-id></mixed-citation></ref><ref id="pone.0136019.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Miyoshi</surname><given-names>S</given-names></name>, <name><surname>Wang</surname><given-names>J</given-names></name>, <name><surname>Katoh</surname><given-names>K</given-names></name>, <name><surname>Senoh</surname><given-names>M</given-names></name>, <name><surname>Mizuno</surname><given-names>T</given-names></name>, <name><surname>Maehara</surname><given-names>Y</given-names></name>. <article-title>An extracellular serine protease produced by Vibrio vulnificus NCIMB 2137, a metalloprotease-gene negative strain isolated from a diseased eel</article-title>. <source>World J Microbiol Biotechnol</source>. <year>2012</year>; <volume>28</volume>: <fpage>1633</fpage>&#x02013;<lpage>1639</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s11274-011-0969-y">10.1007/s11274-011-0969-y</ext-link></comment>
<pub-id pub-id-type="pmid">22805945</pub-id></mixed-citation></ref><ref id="pone.0136019.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Newton</surname><given-names>A</given-names></name>, <name><surname>Kendall</surname><given-names>M</given-names></name>, <name><surname>Vugia</surname><given-names>DJ</given-names></name>, <name><surname>Henao</surname><given-names>OL</given-names></name>, <name><surname>Mahon</surname><given-names>BE</given-names></name>. <article-title>Increasing rates of vibriosis in the United States, 1996&#x02013;2010: review of surveillance data from 2 systems</article-title>. <source>Clin Infect Dis</source>. <year>2012</year>; <volume>54</volume>: <fpage>S391</fpage>&#x02013;<lpage>395</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/cid/cis243">10.1093/cid/cis243</ext-link></comment>
<pub-id pub-id-type="pmid">22572659</pub-id></mixed-citation></ref><ref id="pone.0136019.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Chuang</surname><given-names>YC</given-names></name>, <name><surname>Yuan</surname><given-names>CY</given-names></name>, <name><surname>Liu</surname><given-names>CY</given-names></name>, <name><surname>Lan</surname><given-names>CK</given-names></name>, <name><surname>Huang</surname><given-names>AH</given-names></name>. <article-title>Vibrio vulnificus infection in Taiwan: report of 28 cases and review of clinical manifestations and treatment</article-title>. <source>Clin Infect Dis</source>. <year>1992</year>; <volume>15</volume>: <fpage>271</fpage>&#x02013;<lpage>276</lpage>. <pub-id pub-id-type="pmid">1520762</pub-id></mixed-citation></ref><ref id="pone.0136019.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>YC</given-names></name>, <name><surname>Hor</surname><given-names>LI</given-names></name>, <name><surname>Chiu</surname><given-names>HY</given-names></name>, <name><surname>Lee</surname><given-names>JW</given-names></name>, <name><surname>Shieh</surname><given-names>SJ</given-names></name>. <article-title>Prognostic factor of mortality and its clinical implications in patients with necrotizing fasciitis caused by Vibrio vulnificus</article-title>. <source>Eur J Clin Microbiol Infect Dis</source>. <year>2014</year>; <volume>33</volume>: <fpage>1011</fpage>&#x02013;<lpage>1018</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10096-013-2039-x">10.1007/s10096-013-2039-x</ext-link></comment>
<pub-id pub-id-type="pmid">24419406</pub-id></mixed-citation></ref><ref id="pone.0136019.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Hong</surname><given-names>G</given-names></name>, <name><surname>Wu</surname><given-names>B</given-names></name>, <name><surname>Lu</surname><given-names>C</given-names></name>, <name><surname>Li</surname><given-names>M</given-names></name>, <name><surname>Zhao</surname><given-names>G</given-names></name>, <name><surname>Lu</surname><given-names>Z</given-names></name>. <article-title>Emergency treatment of 16 patients with necrotizing fasciitis caused by Vibrio vulnificus infection complicated with septic shock</article-title>. <source>Chin Med J (Engl)</source>. <year>2014</year>; <volume>127</volume>: <fpage>1984</fpage>&#x02013;<lpage>1986</lpage>.<pub-id pub-id-type="pmid">24824268</pub-id></mixed-citation></ref><ref id="pone.0136019.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Kuo</surname><given-names>Chou TN</given-names></name>, <name><surname>Chao</surname><given-names>WN</given-names></name>, <name><surname>Yang</surname><given-names>C</given-names></name>, <name><surname>Wong</surname><given-names>RH</given-names></name>, <name><surname>Ueng</surname><given-names>KC</given-names></name>, <name><surname>Chen</surname><given-names>SC</given-names></name>. <article-title>Predictors of mortality in skin and soft-tissue infections caused by Vibrio vulnificus</article-title>. <source>World J Surg</source>. <year>2010</year>; <volume>34</volume>: <fpage>1669</fpage>&#x02013;<lpage>1675</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00268-010-0455-y">10.1007/s00268-010-0455-y</ext-link></comment>
<pub-id pub-id-type="pmid">20151130</pub-id></mixed-citation></ref><ref id="pone.0136019.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Chao</surname><given-names>WN</given-names></name>, <name><surname>Tsai</surname><given-names>CF</given-names></name>, <name><surname>Chang</surname><given-names>HR</given-names></name>, <name><surname>Chan</surname><given-names>KS</given-names></name>, <name><surname>Su</surname><given-names>CH</given-names></name>, <name><surname>Lee</surname><given-names>YT</given-names></name>, <etal>et al</etal>
<article-title>Impact of timing of surgery on outcome of Vibrio vulnificus-related necrotizing fasciitis</article-title>. <source>Am J Surg</source>. <year>2013</year>; <volume>206</volume>: <fpage>32</fpage>&#x02013;<lpage>39</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.amjsurg.2012.08.008">10.1016/j.amjsurg.2012.08.008</ext-link></comment>
<pub-id pub-id-type="pmid">23414632</pub-id></mixed-citation></ref><ref id="pone.0136019.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>SC</given-names></name>, <name><surname>Chan</surname><given-names>KS</given-names></name>, <name><surname>Chao</surname><given-names>WN</given-names></name>, <name><surname>Wang</surname><given-names>PH</given-names></name>, <name><surname>Lin</surname><given-names>DB</given-names></name>, <name><surname>Ueng</surname><given-names>KC</given-names></name>, <etal>et al</etal>
<article-title>Clinical outcomes and prognostic factors for patients with Vibrio vulnificus infections requiring intensive care: a 10-yr retrospective study</article-title>. <source>Crit Care Med</source>. <year>2010</year>; <volume>38</volume>: <fpage>1984</fpage>&#x02013;<lpage>1990</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/CCM.0b013e3181eeda2c">10.1097/CCM.0b013e3181eeda2c</ext-link></comment>
<pub-id pub-id-type="pmid">20657269</pub-id></mixed-citation></ref><ref id="pone.0136019.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Tsai</surname><given-names>J</given-names></name>, <name><surname>Ford</surname><given-names>ES</given-names></name>, <name><surname>Li</surname><given-names>C</given-names></name>, <name><surname>Pearson</surname><given-names>WS</given-names></name>, <name><surname>Zhao</surname><given-names>G</given-names></name>. <article-title>Binge drinking and suboptimal self-rated health among adult drinkers</article-title>. <source>Alcohol Clin Exp Res</source>. <year>2010</year>; <volume>34</volume>: <fpage>1465</fpage>&#x02013;<lpage>1471</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1530-0277.2010.01231.x">10.1111/j.1530-0277.2010.01231.x</ext-link></comment>
<pub-id pub-id-type="pmid">20528820</pub-id></mixed-citation></ref><ref id="pone.0136019.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Levy</surname><given-names>MM</given-names></name>, <name><surname>Fink</surname><given-names>MP</given-names></name>, <name><surname>Marshall</surname><given-names>JC</given-names></name>, <name><surname>Abraham</surname><given-names>E</given-names></name>, <name><surname>Angus</surname><given-names>D</given-names></name>, <name><surname>Cook</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference</article-title>. <source>Crit Care Med</source>. <year>2003</year>; <volume>31</volume>: <fpage>1250</fpage>&#x02013;<lpage>1256</lpage>. <pub-id pub-id-type="pmid">12682500</pub-id></mixed-citation></ref><ref id="pone.0136019.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Tsai</surname><given-names>YH</given-names></name>, <name><surname>Hsu</surname><given-names>RW</given-names></name>, <name><surname>Huang</surname><given-names>KC</given-names></name>, <name><surname>Huang</surname><given-names>TJ</given-names></name>. <article-title>Laboratory indicators for early detection and surgical treatment of vibrio necrotizing fasciitis</article-title>. <source>Clin Orthop Relat Res</source>. <year>2010</year>; <volume>468</volume>: <fpage>2230</fpage>&#x02013;<lpage>2237</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s11999-010-1311-y">10.1007/s11999-010-1311-y</ext-link></comment>
<pub-id pub-id-type="pmid">20232179</pub-id></mixed-citation></ref></ref-list></back></article>